EpiThany is dedicated to the advancement of innovative therapies to improve the lives of cancer patients. EpiThany's groundbreaking technology enables the targeting of a multitude of tumor antigens across a spectrum of cancers, driving Th1-selective (tumor-eradicating) immune responses. EpiThany was launched in 2014 on the R&D platform developed at the Tumor Vaccine Group (TVG) at the University of Washington by pioneering cancer vaccine researcher Nora Disis, scientific co-founder of the company. For more information, visit www.epithany.com.
Co-Founder & CEO: William Watt
COO: David Poston
VP, Corporate Development: Aaron Coe
Please click here for EpiThany job opportunities.